• Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

    Source: Nasdaq GlobeNewswire / 10 Feb 2022 08:00:01   America/New_York

    CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022 at 9:20 a.m. ET.

    A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.

    About Fulcrum Therapeutics
    Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

    Please visit www.fulcrumtx.com.

    Contact:

    Investors:
    Christi Waarich
    Director, Investor Relations
    cwaarich@fulcrumtx.com 
    617-651-8664


    Primary Logo

Share on,